001     147400
005     20240229121831.0
024 7 _ |a 10.1186/s12872-019-1187-z
|2 doi
024 7 _ |a pmid:31664920
|2 pmid
024 7 _ |a altmetric:69563062
|2 altmetric
037 _ _ |a DKFZ-2019-02517
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Schmidt, Amand F
|0 0000-0003-1327-0424
|b 0
245 _ _ |a Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.
260 _ _ |a London
|c 2019
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1582282111_27317
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9.Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration.The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57; 1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer's disease - outcomes for which large-scale trial data were unavailable.Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown; although precision was moderate.
536 _ _ |a 323 - Metabolic Dysfunction as Risk Factor (POF3-323)
|0 G:(DE-HGF)POF3-323
|c POF3-323
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Holmes, Michael V
|b 1
700 1 _ |a Preiss, David
|b 2
700 1 _ |a Swerdlow, Daniel I
|b 3
700 1 _ |a Denaxas, Spiros
|b 4
700 1 _ |a Fatemifar, Ghazaleh
|b 5
700 1 _ |a Faraway, Rupert
|b 6
700 1 _ |a Finan, Chris
|b 7
700 1 _ |a Valentine, Dennis
|b 8
700 1 _ |a Fairhurst-Hunter, Zammy
|b 9
700 1 _ |a Hartwig, Fernando Pires
|b 10
700 1 _ |a Horta, Bernardo Lessa
|b 11
700 1 _ |a Hypponen, Elina
|b 12
700 1 _ |a Power, Christine
|b 13
700 1 _ |a Moldovan, Max
|b 14
700 1 _ |a van Iperen, Erik
|b 15
700 1 _ |a Hovingh, Kees
|b 16
700 1 _ |a Demuth, Ilja
|b 17
700 1 _ |a Norman, Kristina
|b 18
700 1 _ |a Steinhagen-Thiessen, Elisabeth
|b 19
700 1 _ |a Demuth, Juri
|b 20
700 1 _ |a Bertram, Lars
|b 21
700 1 _ |a Lill, Christina M
|b 22
700 1 _ |a Coassin, Stefan
|b 23
700 1 _ |a Willeit, Johann
|b 24
700 1 _ |a Kiechl, Stefan
|b 25
700 1 _ |a Willeit, Karin
|b 26
700 1 _ |a Mason, Dan
|b 27
700 1 _ |a Wright, John
|b 28
700 1 _ |a Morris, Richard
|b 29
700 1 _ |a Wanamethee, Goya
|b 30
700 1 _ |a Whincup, Peter
|b 31
700 1 _ |a Ben-Shlomo, Yoav
|b 32
700 1 _ |a McLachlan, Stela
|b 33
700 1 _ |a Price, Jackie F
|b 34
700 1 _ |a Kivimaki, Mika
|b 35
700 1 _ |a Welch, Catherine
|b 36
700 1 _ |a Sanchez-Galvez, Adelaida
|b 37
700 1 _ |a Marques-Vidal, Pedro
|b 38
700 1 _ |a Nicolaides, Andrew
|b 39
700 1 _ |a Panayiotou, Andrie G
|b 40
700 1 _ |a Onland-Moret, N Charlotte
|b 41
700 1 _ |a van der Schouw, Yvonne T
|b 42
700 1 _ |a Matullo, Giuseppe
|b 43
700 1 _ |a Fiorito, Giovanni
|b 44
700 1 _ |a Guarrera, Simonetta
|b 45
700 1 _ |a Sacerdote, Carlotta
|b 46
700 1 _ |a Wareham, Nicholas J
|b 47
700 1 _ |a Langenberg, Claudia
|b 48
700 1 _ |a Scott, Robert A
|b 49
700 1 _ |a Luan, Jian'an
|b 50
700 1 _ |a Bobak, Martin
|b 51
700 1 _ |a Malyutina, Sofia
|b 52
700 1 _ |a Pająk, Andrzej
|b 53
700 1 _ |a Kubinova, Ruzena
|b 54
700 1 _ |a Tamosiunas, Abdonas
|b 55
700 1 _ |a Pikhart, Hynek
|b 56
700 1 _ |a Grarup, Niels
|b 57
700 1 _ |a Pedersen, Oluf
|b 58
700 1 _ |a Hansen, Torben
|b 59
700 1 _ |a Linneberg, Allan
|b 60
700 1 _ |a Jess, Tine
|b 61
700 1 _ |a Cooper, Jackie
|b 62
700 1 _ |a Humphries, Steve E
|b 63
700 1 _ |a Brilliant, Murray
|b 64
700 1 _ |a Kitchner, Terrie
|b 65
700 1 _ |a Hakonarson, Hakon
|b 66
700 1 _ |a Carrell, David S
|b 67
700 1 _ |a McCarty, Catherine A
|b 68
700 1 _ |a Lester, Kirchner H
|b 69
700 1 _ |a Larson, Eric B
|b 70
700 1 _ |a Crosslin, David R
|b 71
700 1 _ |a de Andrade, Mariza
|b 72
700 1 _ |a Roden, Dan M
|b 73
700 1 _ |a Denny, Joshua C
|b 74
700 1 _ |a Carty, Cara
|b 75
700 1 _ |a Hancock, Stephen
|b 76
700 1 _ |a Attia, John
|b 77
700 1 _ |a Holliday, Elizabeth
|b 78
700 1 _ |a Scott, Rodney
|b 79
700 1 _ |a Schofield, Peter
|b 80
700 1 _ |a O'Donnell, Martin
|b 81
700 1 _ |a Yusuf, Salim
|b 82
700 1 _ |a Chong, Michael
|b 83
700 1 _ |a Pare, Guillaume
|b 84
700 1 _ |a van der Harst, Pim
|b 85
700 1 _ |a Said, M Abdullah
|b 86
700 1 _ |a Eppinga, Ruben N
|b 87
700 1 _ |a Verweij, Niek
|b 88
700 1 _ |a Snieder, Harold
|b 89
700 1 _ |a authors, Lifelines Cohort
|b 90
|e Collaboration Author
700 1 _ |a Christen, Tim
|b 91
700 1 _ |a Mook-Kanamori, D. O.
|b 92
700 1 _ |a Consortium, ICBP
|b 93
|e Collaboration Author
700 1 _ |a Gustafsson, Stefan
|b 94
700 1 _ |a Lind, Lars
|b 95
700 1 _ |a Ingelsson, Erik
|b 96
700 1 _ |a Pazoki, Raha
|b 97
700 1 _ |a Franco, Oscar
|b 98
700 1 _ |a Hofman, Albert
|b 99
700 1 _ |a Uitterlinden, Andre
|b 100
700 1 _ |a Dehghan, Abbas
|b 101
700 1 _ |a Teumer, Alexander
|b 102
700 1 _ |a Baumeister, Sebastian
|b 103
700 1 _ |a Dörr, Marcus
|b 104
700 1 _ |a Lerch, Markus M
|b 105
700 1 _ |a Völker, Uwe
|b 106
700 1 _ |a Völzke, Henry
|b 107
700 1 _ |a Ward, Joey
|b 108
700 1 _ |a Pell, Jill P
|b 109
700 1 _ |a Meade, Tom
|b 110
700 1 _ |a Christophersen, Ingrid E
|b 111
700 1 _ |a Maitland-van der Zee, Anke H
|b 112
700 1 _ |a Baranova, Ekaterina V
|b 113
700 1 _ |a Young, Robin
|b 114
700 1 _ |a Ford, Ian
|b 115
700 1 _ |a Campbell, Archie
|b 116
700 1 _ |a Padmanabhan, Sandosh
|b 117
700 1 _ |a Bots, Michiel L
|b 118
700 1 _ |a Grobbee, Diederick E
|b 119
700 1 _ |a Froguel, Philippe
|b 120
700 1 _ |a Thuillier, Dorothée
|b 121
700 1 _ |a Roussel, Ronan
|b 122
700 1 _ |a Bonnefond, Amélie
|b 123
700 1 _ |a Cariou, Bertrand
|b 124
700 1 _ |a Smart, Melissa
|b 125
700 1 _ |a Bao, Yanchun
|b 126
700 1 _ |a Kumari, Meena
|b 127
700 1 _ |a Mahajan, Anubha
|b 128
700 1 _ |a Hopewell, Jemma C
|b 129
700 1 _ |a Seshadri, Sudha
|b 130
700 1 _ |a ISGC, METASTROKE Consortium of the
|b 131
|e Collaboration Author
700 1 _ |a Dale, Caroline
|b 132
700 1 _ |a Costa, Rui Providencia E
|b 133
700 1 _ |a Ridker, Paul M
|b 134
700 1 _ |a Chasman, Daniel I
|b 135
700 1 _ |a Reiner, Alex P
|b 136
700 1 _ |a Ritchie, Marylyn D
|b 137
700 1 _ |a Lange, Leslie A
|b 138
700 1 _ |a Cornish, Alex J
|b 139
700 1 _ |a Dobbins, Sara E
|b 140
700 1 _ |a Hemminki, Kari
|0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
|b 141
|u dkfz
700 1 _ |a Kinnersley, Ben
|b 142
700 1 _ |a Sanson, Marc
|b 143
700 1 _ |a Labreche, Karim
|b 144
700 1 _ |a Simon, Matthias
|b 145
700 1 _ |a Bondy, Melissa
|b 146
700 1 _ |a Law, Philip
|b 147
700 1 _ |a Speedy, Helen
|b 148
700 1 _ |a Allan, James
|b 149
700 1 _ |a Li, Ni
|b 150
700 1 _ |a Went, Molly
|b 151
700 1 _ |a Weinhold, Niels
|b 152
700 1 _ |a Morgan, Gareth
|b 153
700 1 _ |a Sonneveld, Pieter
|b 154
700 1 _ |a Nilsson, Björn
|b 155
700 1 _ |a Goldschmidt, Hartmut
|b 156
700 1 _ |a Sud, Amit
|b 157
700 1 _ |a Engert, Andreas
|b 158
700 1 _ |a Hansson, Markus
|b 159
700 1 _ |a Hemingway, Harry
|b 160
700 1 _ |a Asselbergs, Folkert W
|b 161
700 1 _ |a Patel, Riyaz S
|b 162
700 1 _ |a Keating, Brendan J
|b 163
700 1 _ |a Sattar, Naveed
|b 164
700 1 _ |a Houlston, Richard
|b 165
700 1 _ |a Casas, Juan P
|b 166
700 1 _ |a Hingorani, Aroon D
|b 167
773 _ _ |a 10.1186/s12872-019-1187-z
|g Vol. 19, no. 1, p. 240
|0 PERI:(DE-600)2059859-2
|n 1
|p 240
|t BMC cardiovascular disorders
|v 19
|y 2019
|x 1471-2261
909 C O |p VDB
|o oai:inrepo02.dkfz.de:147400
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 141
|6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
913 1 _ |a DE-HGF
|l Herz-Kreislauf-Stoffwechselerkrankungen
|1 G:(DE-HGF)POF3-320
|0 G:(DE-HGF)POF3-323
|2 G:(DE-HGF)POF3-300
|v Metabolic Dysfunction as Risk Factor
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BMC CARDIOVASC DISOR : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21